While phototherapy has been shown to have a positive effect on vitiligo as it works to reduce or prevent the destruction of skin cells, treatment done in the hospital can be long-term and require a number of visits.
It's been proven vitiligo, the autoimmune skin depigmentation condition, can be treated through hospital-based phototherapy, but recent studies show that self-treating, home-based therapy's adherence to treatment is significantly better.
While phototherapy has been shown to have a positive effect on vitiligo as it works to reduce or prevent the destruction of skin cells, treatment done in the hospital can be long-term and require a number of visits.
Self-treatment using home-based phototherapy can be a more convenient alternative, according to a review published in Photodermatology, Photoimmunology & Photomedicine in this month.
Authors of the systematic review colleced data to assess the effectiveness and safety of home-based phototherapy for vitiligo. Research was conducted on Medline, Scopus and The Cochrane Library for randomised controlled trials (RCT).
Three studies were reviewed in this search: two compared home-based with institution-based phototherapy, and one compared home-based phototherapy with placebo. In total, there were 195 participants aging from 5 to 71 years with a clinical diagnosis of vitiligo.
Findings on effectiveness were contradictory across studies with variable rates of repigmentation. There ended up being no significant difference in repigmentation rates between the groups, ranging from <25% to >75% repigmentation of lesions, but adherence to treatment schedules resulted to stand out significantly better in home-based groups due to having any-time access.
In one of the studies, it was found that 68% of participants in the active phototherapy group and 64% of participants in the placebo group would use the hand-held home-based phototherapy device again and recommend it to others because self-administration allowed flexibility of treatment.
Between all three studies, 13% of participants in the institution-based groups discontinued treatment due to a lack of time or missing too many treatments, compared to 0% of the home-based groups, with one study accrediting this to the convenience of treatment.
An author of the review explained the convenience and adverse rates were significantly higher and more severe across home-based phototherapy due to "overenthusiastic use." However, overuse does not result in any significant benefit in repigmentation compared to institution-based phototherapy; the clinical benefit of greater adherence is unclear.
According to the review, home-based phototherapy may have a place in the treatment of vitiligo due to its convenience, particularly for individuals who are unwilling or unable to attend hospital regularly. However, it's suggested the effectiveness and safety of home-based phototherapy should be explored further in large-scale, good-quality RCTs, before being recommended for clinical practice use.
Ruxolitinib Cream Proves Safe for Young Children with Atopic Dermatitis
July 22nd 2024These results were found in the TRuE-AD3 study that was presented at the Society for Pediatric Dermatology meeting earlier this month, revealing the latest round of data collected in the TRuE-AD1 and TRuE-AD2 series of studies.
Read More
Study Reveals Severe Impact of Atopic Dermatitis on Women's Quality of Life and Reproductive Health
July 15th 2024Although AD is a common condition, it’s impact on sexual function and reproductive health is not well understood. In addition, many women with AD are undertreated during pregnancy due to concerns about medication side effects.
Read More
High Sodium Intake Associated to Increased Risk of Severe Atopic Dermatitis
June 20th 2024Researchers who conducted the study, of the Universities of California in San Francisco and Berkley, suggest that cutting down on sodium could be a more cost-effective and low-risk way to help manage AD.
Read More
Highly Contagious and Hard-to-Treat Fungal Skin Infections Are Emerging, Experts Warn
June 6th 2024Experts are urging healthcare providers to be aware of these two new forms of ringworm or jock itch, known as Trichophyton mentagrophytes type VII (TMVII) and Trichophyton indotineae or T. indotineae.
Read More